Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3671-3681

  Pan, Jingxuan ^a   She, Miaorong ^a   Xu, Zhi Xiang ^a   Sun, Lily ^a   Yeung, Sai Ching Jim ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ACETYLCYSTEINE; ATM PROTEIN; BRCA1 PROTEIN; CAFFEINE; CHECKPOINT KINASE RAD3; DEFEROXAMINE; DNA; DNA DEPENDENT PROTEIN KINASE; DOXYCYCLINE; MANUMYCIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; NIBRIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; EVALUATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INDUCTION;

ALKYL AND ARYL TRANSFERASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HCT116 CELLS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; POLYENES; POLYUNSATURATED ALKAMIDES; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; RHOB GTP-BINDING PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 18144363210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2744     Document Type: Article

References (51)

1. Bishop WR, Kirschmeier P, Baum C. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation. Cancer Biol Ther 2003;2:S96-104.
2. Brunner TB, Hahn SM, Gupta AK, et al. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003;63:5656-68.
3. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997;37:143-66.
4. Sebti S, Hamilton AD. Inhibitors of prenyl trausferases. Curr Opin Oncol 1997;9:557-61.
5. Servais P, Gulbis B, Fokan D, Galand P. Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. Inter J Cancer 1998;76:601-8.
6. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999;59:5492-6.
7. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000;20:6105-13.
8. Kamasani U, Huang M, Duhadaway JB, et al. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res 2004;64:8389-96.
9. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000;20:139-48.
10. Hu W, Wu W, Verschraegen CF, et al. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 2003;3:1904-11.
11. Hu W, Wu W, Yeung SC, et al. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res 2002;22:665-72.
12. Hara M, Akasaka K, Akinaga S, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A 1993;90:2281-5.
13. Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. J Cell Biochem Suppl 1997;27:12-9.
14. Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002;2:303-23.
15. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000;60:650-6.
16. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001;86:4731-40.
17. Yang HL, Pan JX, Sun L, Yeung SC. p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:763-72.
18. 3H]thymidine uptake in HTC-4 and LLC-L1 tumor cells. J Surg Res 1996;61:367-72.
19. Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood 1991;77:1064-70.
20. Selleri C, Maciejewski JP, Montuori N, et al. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood 2003;102:1490-8.
21. Fritz G, Kaina B, Aktories K. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 1995;270:25172-7.
22. Liu A, Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A 2001;98:6192-7.
23. Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-84.
24. Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996;81:3650-3.
25. Ziv Y, Bar-Shira A, Pecker I, et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997;15:159-67.
26. Kurimasa A, Kumano S, Boubnov NV, et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol Cell Biol 1999;19:3877-84.
27. Nghiem P, Park PK, Kim YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002;277:4428-34.
28. Nakatsubo N, Kojima H, Kikuchi K, et al. Direct evidence of nitric oxide production from bovine aortic endothelial cells using new fluorescence indicators: diaminofluoresceins. FEBS Lett 1998;427:263-6.
29. Budd SL, Castilho RF, Nicholls DG. Mitochondrial membrane potential and hydroethidine-monitored superoxide generation in cultured cerebellar granule cells. FEBS Lett 1997;415:21-4.
30. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390-5.
31. Barret JM, Salles B, Provot C, Hill BT. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis 1997;18:2441-5.
32. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
33. Paull TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
34. Redon C, Pilch D, Rogakou E, et al. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002;12:162-9.
35. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23:5706-15.
36. Salles B, Provot C, Calsou P, et al. A chemiluminescent microplate assay to detect DNA damage induced by genotoxic treatments. Anal Biochem 1995;232:37-42.
37. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
38. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-508.
39. Baumann P, West SC. DNA end-joining catalyzed by human cell-free extracts. Proc Natl Acad Sci U S A 1998;95:14066-70.
40. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 2002;3:317-27.
41. Chan DW, Chen BP, Prithivirajsingh S, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002;16:2333-8.
42. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
43. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82.
44. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-82.
45. Morley N, Curnow A, Salter L, Campbell S, Gould D. N-acetyl-L-cysteine prevents DNA damage induced by UVA, UVB and visible radiation in human fibroblasts. J Photochem Photobiol B 2003;72:55-60.
46. Burney S, Niles JC, Dedon PC, Tannenbaum SR. DNA damage in deoxynucleosides and oligonucleotides treated with peroxynitrite. Chem Res Toxicol 1999;12:513-20.
47. Scully R, Ganesan S, Vlasakova K, et al. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999;4:1093-9.
48. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
49. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
50. Fedier A, Steiner RA, Schwarz VA, et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003;22:1169-73.
51. Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs 2001;10:2105-16.